Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

Kassel, Germany and Cambridge, MA, USA November 7, 2019 – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in m...

Read More

Ultivue expands UltiMapper™ portfolio of multiplex marker assays for comprehensive phenotyping of the immune microenvironment and tissue immuno-profiling research

CAMBRIDGE, Mass, November 6, 2019 – Ultivue, a leading developer of tissue biomarker identification and quantification assays for translational research and pathology labs, today announced the expansion of its UltiMappe...

Read More

Ultivue Raises $22 Million in Series C Funding

CAMBRIDGE, Mass, June 27, 2019 – Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Seri...

Read More

Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis

CAMBRIDGE, Mass – March 29, 2019. Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI)...

Read More

Ultivue releases breakthrough innovations for multiplex IHC: 16-marker whole-slide visualization and high marker co-localization in FFPE tissue

CAMBRIDGE, Mass, March 28, 2018 – Ultivue today unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker ...

Read More

Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl

CAMBRIDGE, Mass, February 21, 2019 – Ultivue, a developer of tissue biomarker identification and quantification assays for pathology and translational research labs, today announced that it has expanded its commercial f...

Read More

Ultivue Expands UltiMapper™ Platform of Multiplex Assays for Tissue Immuno-Profiling

CAMBRIDGE, Mass, January 24, 2019 – Ultivue, a developer of tissue biomarker identification and quantification assays for translational research and pathology labs, today announced two new additions to its existing Ulti...

Read More

A retrospective study from Yale School of Medicine shows association with overall survival in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockade using a panel of CD8, CD68, PD-L1 in a novel tissue-based multiplex assay

CAMBRIDGE, Mass, November 8, 2018 – Ultivue announced today that the Yale School of Medicine will present data highlighting the utility of a CD8, CD68, PD-L1 quantitative multiplex immunohistochemistry (IHC) panel. In t...

Read More

Ultivue to release a breakthrough 9-Color multiplex IHC panel achieving same day sample-to-analysis at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018

CAMBRIDGE, Mass, November 7, 2018 – Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its proprietary InSituPl...

Read More

Unlocking the complexities of cancer biology with BOND RX and Ultivue.

Melbourne, Australia and Cambridge, Massachusetts – October 25, 2018 | Leica Biosystems and Ultivue begin Co-Marketing of UltiMapper™ Assay on the BOND RX enabling single-step automated multiplexing in under 6 hou...

Read More